What is BioStable Science & Engineering?
BioStable Science & Engineering is a cardiovascular device company dedicated to the development and commercialization of proprietary valve repair technologies. These technologies aim to offer a viable alternative to valve replacement for patients suffering from aortic valve disease. The company's HAART Aortic Repair Technologies are engineered to streamline and standardize the aortic valve repair process, empowering surgeons to provide the well-documented clinical advantages of valve repair to patients undergoing surgical correction for aortic insufficiency or aortic aneurysm. This focus positions BioStable Science & Engineering within the competitive medical device sector, specifically targeting the significant market for cardiac valve interventions.
How much funding has BioStable Science & Engineering raised?
BioStable Science & Engineering has raised a total of $14M across 3 funding rounds:
Series A
$5.5M
Series B
$4.3M
Series C
$4.2M
Series A (2008): $5.5M with participation from Sante Ventures
Series B (2015): $4.3M led by Sante Ventures
Series C (2020): $4.2M supported by Orlando Health Ventures and Rex Health Ventures
Key Investors in BioStable Science & Engineering
Orlando Health Ventures
Orlando Health Ventures is an investment arm focused on healthcare innovation, likely seeking to support companies that align with Orlando Health's strategic objectives in patient care and medical technology.
Rex Health Ventures
Rex Health Ventures, associated with UNC REX Healthcare, invests in ventures that enhance healthcare delivery and patient outcomes, particularly within the North Carolina region and beyond.
Sante Ventures
Sante Ventures is a prominent investment firm specializing in innovative healthcare and technology companies, with a strong focus on the Biotech, Medtech, and Healthtech sectors, aiming to advance patient health outcomes.
What's next for BioStable Science & Engineering?
The recent major strategic investment signifies a critical growth phase for BioStable Science & Engineering, likely enabling the company to accelerate its commercialization efforts and further refine its HAART Aortic Repair Technologies. This enterprise-level funding suggests confidence from investors in the company's technology and market potential. Future developments will likely involve expanding clinical adoption, navigating regulatory pathways, and potentially scaling manufacturing capabilities to meet anticipated demand. The company's trajectory points towards becoming a key player in the field of minimally invasive cardiac valve repair.
See full BioStable Science & Engineering company page
